Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201467 | 0.89 | MCHR1 (0.43) | KDRNR2E1MCHR1ROCK2 | |
| SCHEMBL1408282 | 0.86 | KDR (0.47) | KDRAURKAAURKBMCHR1PIK3C3 | |
| SCHEMBL2203105 | 0.85 | KDR (0.47) | KDRAURKAAURKBNR2E1ROCK2 | |
| SCHEMBL2202607 | 0.83 | AURKA (0.50) | KDRAURKAAURKBNR2E1MCHR1 | |
| SCHEMBL2204785 | 0.80 | MAPT (0.38) | NR2E1MCHR1 | |
| SCHEMBL2201767 | 0.80 | KDR (0.48) | KDRAURKAAURKBPIK3C3ROCK2 | |
| SCHEMBL2203664 | 0.80 | NR2E1 (0.43) | NR2E1MCHR1 | |
| SCHEMBL2202269 | 0.79 | RORC (0.52) | KDRAURKAAURKBROCK2NPC1 | |
| SCHEMBL2200833 | 0.79 | AURKA (0.52) | KDRAURKAAURKBNR2E1NPC1 | |
| SCHEMBL1408536 | 0.78 | AURKA (0.74) | KDRAURKAAURKBNR2E1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | claimed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | KDR 110/4885AURKA 148/4885AURKB 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.